[go: up one dir, main page]

CN111527109A - 以抗体Fc区为骨架的融合蛋白二聚体及其应用 - Google Patents

以抗体Fc区为骨架的融合蛋白二聚体及其应用 Download PDF

Info

Publication number
CN111527109A
CN111527109A CN201880084110.7A CN201880084110A CN111527109A CN 111527109 A CN111527109 A CN 111527109A CN 201880084110 A CN201880084110 A CN 201880084110A CN 111527109 A CN111527109 A CN 111527109A
Authority
CN
China
Prior art keywords
polypeptide chain
antibody
seq
fusion protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880084110.7A
Other languages
English (en)
Other versions
CN111527109B (zh
Inventor
李中道
宋立新
张望
张亚峰
汪东亮
柳振宇
章方良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Jinsirui Science and Technology Biology Corp
Original Assignee
Nanjing Jinsirui Science and Technology Biology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Jinsirui Science and Technology Biology Corp filed Critical Nanjing Jinsirui Science and Technology Biology Corp
Publication of CN111527109A publication Critical patent/CN111527109A/zh
Application granted granted Critical
Publication of CN111527109B publication Critical patent/CN111527109B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

提供了一种以抗体Fc区为骨架的融合蛋白二聚体，包括第一和第二多肽链，其中所述第一多肽链包括第一抗体Fc区和与所述第一抗体Fc区融合的一个或多个单域抗体；所述第二多肽链包括第二抗体Fc区和与所述第二抗体Fc区融合的一个或多个单域抗体；所述第一多肽链和/或第二多肽链还包括与各自抗体Fc区融合的细胞因子。还提供了该融合蛋白二聚体在制备治疗肿瘤的免疫治疗药物中的应用。所述Fc融合蛋白异源二聚体，不仅提升了单域抗体的活性，而且明显改善了细胞因子的生物学活性；并利用抗体的靶向特异性，有效增强了细胞因子的靶向运输，减弱了细胞毒性，从而具有更佳的抗肿瘤潜力。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN201880084110.7A 2017-12-26 2018-12-26 以抗体Fc区为骨架的融合蛋白二聚体及其应用 Active CN111527109B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711431542 2017-12-26
CN2017114315424 2017-12-26
PCT/CN2018/123878 WO2019129053A1 (zh) 2017-12-26 2018-12-26 以抗体Fc区为骨架的融合蛋白二聚体及其应用

Publications (2)

Publication Number Publication Date
CN111527109A true CN111527109A (zh) 2020-08-11
CN111527109B CN111527109B (zh) 2024-11-01

Family

ID=67063142

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880084110.7A Active CN111527109B (zh) 2017-12-26 2018-12-26 以抗体Fc区为骨架的融合蛋白二聚体及其应用

Country Status (5)

Country Link
US (1) US11970537B2 (zh)
EP (1) EP3733716A4 (zh)
JP (1) JP7336457B2 (zh)
CN (1) CN111527109B (zh)
WO (1) WO2019129053A1 (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114945586A (zh) * 2020-01-21 2022-08-26 张晋宇 一种药物组合物及其用途
CN115838432A (zh) * 2022-07-08 2023-03-24 浙江大学 一种靶向调控抗原特异性t细胞的融合蛋白及应用
CN116554356A (zh) * 2023-05-16 2023-08-08 武汉大学 一种hyperIL-15与sCD4及Fc的融合蛋白及其应用
WO2024032617A1 (zh) * 2022-08-09 2024-02-15 三生国健药业（上海）股份有限公司 异多聚体蛋白质及其制备方法
CN117645673A (zh) * 2023-11-22 2024-03-05 武汉大学 一种IL-21与sCD4及Fc的融合蛋白及其应用
CN118359730A (zh) * 2023-01-17 2024-07-19 上海君赛生物科技有限公司 包含细胞因子的靶向型融合蛋白

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
AU2018297248A1 (en) 2017-07-03 2020-02-20 Torque Therapeutics, Inc. Fusion molecules targeting immune regulatory cells and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
KR102839330B1 (ko) * 2018-01-15 2025-07-30 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
JP2021530243A (ja) 2018-07-25 2021-11-11 アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. 新規ｉｌ−２１プロドラッグおよびそれを使用する方法
EP3856764A4 (en) 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
CN114008082A (zh) * 2019-06-24 2022-02-01 南京金斯瑞生物科技有限公司 单克隆抗体-细胞因子融合蛋白二聚体及其应用
EP3998287A4 (en) * 2019-07-08 2023-08-09 Nanjing GenScript Biotech Co., Ltd. ANTI-CD47/ANTI-PD-1 BISPECIFIC ANTIBODY, METHOD FOR PREPARATION AND USE
CN112210014B (zh) 2019-07-12 2022-10-11 北京科诺科服生物科技有限公司 一种用于治疗动物肿瘤的融合蛋白及组合物
WO2021062406A1 (en) * 2019-09-28 2021-04-01 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
CN115916233A (zh) * 2019-10-03 2023-04-04 Xencor股份有限公司 靶向IL-12异源二聚体Fc融合蛋白
JP2023509708A (ja) 2020-01-03 2023-03-09 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
AU2021206449A1 (en) 2020-01-10 2022-07-21 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
EP4090687A4 (en) * 2020-01-19 2024-02-21 Nanjing GenScript Biotech Co., Ltd. Multispecific anti-claudin-18.2 constructs and uses thereof
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
JP7771076B2 (ja) * 2020-04-01 2025-11-17 エクシリオ デベロップメント， インコーポレイテッド マスクされたｉｌ－１２サイトカイン及びその切断産物
EP4149554A4 (en) 2020-05-13 2024-05-29 Bonum Therapeutics, Inc. Compositions of protein complexes and methods of use thereof
TWI815194B (zh) * 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
IL302276A (en) 2020-10-23 2023-06-01 Asher Biotherapeutics Inc Fusions with cd8 antigen binding molecules for modulating immune cell function
CN112316130B (zh) * 2020-11-05 2023-11-28 武汉科技大学 一种SARS-CoV2粘膜免疫疫苗及其应用
CA3196844A1 (en) 2020-11-25 2022-06-02 Raphael Rozenfeld Tumor-specific cleavable linkers
AU2022275666A1 (en) 2021-05-19 2023-12-07 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
CN117615792A (zh) * 2021-07-09 2024-02-27 明峰治疗股份公司 检查点抑制剂与il-2的缀合物及其用途
KR20240034221A (ko) 2021-07-09 2024-03-13 브라이트 피크 테라퓨틱스 아게 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
KR20240040134A (ko) * 2021-07-09 2024-03-27 브라이트 피크 테라퓨틱스 아게 항체 접합체 및 이의 제조
AU2022307460A1 (en) * 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Checkpoint inhibitors conjugated to il-2, and uses thereof
WO2023011575A1 (zh) * 2021-08-04 2023-02-09 清华大学 一种靶向并杀伤病原体和/或肿瘤细胞的多功能融合蛋白药物
WO2023092006A1 (en) * 2021-11-17 2023-05-25 Good Therapeutics, Inc. Compositions of protein complexes and methods of use thereof
CN116143946B (zh) * 2022-01-05 2025-12-09 赛德特生物制药有限公司 一种用于免疫治疗的新型融合蛋白、基因、重组载体、宿主细胞及应用
JP2025508823A (ja) 2022-02-23 2025-04-10 ブライト ピーク セラピューティクス エージー 免疫抗原特異的ｉｌ－１８免疫サイトカイン及びその使用
WO2024023246A1 (en) * 2022-07-28 2024-02-01 Philogen S.P.A. Antibody binding to pd1
WO2024073435A2 (en) * 2022-09-27 2024-04-04 Anwita Biosciences, Inc. Anti-lag-3/il-2 fusion proteins, encoding polynucleotides, pharmaceutical compositions, and therapeutic applications
EP4605420A1 (en) * 2022-10-20 2025-08-27 Fundación para la Investigación Médica Aplicada Nanobodies for cancer therapy
CN118221803A (zh) * 2022-12-19 2024-06-21 深圳科兴药业有限公司 异源二聚体Fc融合蛋白及其用途
WO2025162454A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体和细胞因子融合蛋白及其应用
WO2025181343A1 (en) 2024-02-29 2025-09-04 Octapharma Ag Cystine knot domain fusion protein dimers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112986A1 (en) * 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
WO2017194438A1 (en) * 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag C-terminally fused tnf family ligand trimer-containing antigen binding molecules

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020122807A1 (en) * 1998-07-07 2002-09-05 Dan Michael D. Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
ATE267215T1 (de) * 1997-12-08 2004-06-15 Lexigen Pharm Corp Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US20020146750A1 (en) * 2000-03-30 2002-10-10 Hoogenboom Hendricus R.J.M. Mucin-1 specific binding members and methods of use thereof
US20020102264A1 (en) * 2000-10-18 2002-08-01 Cheung Nai-Kong V. Uses of monoclonal antibody 8H9
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
US20070003514A1 (en) * 2002-04-05 2007-01-04 The Regents Of The University Of California Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
EP2654792A4 (en) * 2010-12-22 2016-05-11 Abbvie Inc HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
ES2694564T3 (es) * 2011-02-10 2018-12-21 Roche Glycart Ag Polipéptidos de interleucina-2 mutantes
CN103764665A (zh) * 2011-06-28 2014-04-30 怀特黑德生物医学研究所 使用分选酶安装用于蛋白质连接的点击化学柄
CA2918518C (en) * 2013-07-19 2022-08-16 Universiteit Gent Targeted modified il-1 family members
DK3233907T3 (da) * 2014-12-19 2021-06-07 Genmab As Bispecifikke heterodimeriske proteiner hos gnavere
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
CA3017813C (en) * 2016-03-17 2021-12-07 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
JP7082604B2 (ja) * 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
CN109689087B (zh) * 2016-05-13 2023-04-04 奥里尼斯生物科学私人有限公司 靶向性突变干扰素-β及其用途
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
CN108250303B (zh) * 2016-12-19 2023-01-03 南京金斯瑞生物科技有限公司 单域抗体融合蛋白及其应用
SG11202000939PA (en) * 2017-08-03 2020-02-27 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
EP3856764A4 (en) * 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
EP3864049A1 (en) * 2018-10-11 2021-08-18 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112986A1 (en) * 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
WO2017194438A1 (en) * 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag C-terminally fused tnf family ligand trimer-containing antigen binding molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ELIZABETH ORTIZ-SÁNCHEZ等: "Antibody-cytokine fusion proteins: applications in cancer therapy", EXPERT OPIN BIOL THER., vol. 8, no. 5, pages 609, XP008145785, DOI: 10.1517/14712598.8.5.609 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114945586A (zh) * 2020-01-21 2022-08-26 张晋宇 一种药物组合物及其用途
CN114945586B (zh) * 2020-01-21 2025-01-28 宁波新致生物科技有限公司 一种药物组合物及其用途
CN115838432A (zh) * 2022-07-08 2023-03-24 浙江大学 一种靶向调控抗原特异性t细胞的融合蛋白及应用
CN115838432B (zh) * 2022-07-08 2023-12-08 浙江大学 一种靶向调控抗原特异性t细胞的融合蛋白及应用
WO2024032617A1 (zh) * 2022-08-09 2024-02-15 三生国健药业（上海）股份有限公司 异多聚体蛋白质及其制备方法
CN118359730A (zh) * 2023-01-17 2024-07-19 上海君赛生物科技有限公司 包含细胞因子的靶向型融合蛋白
CN116554356A (zh) * 2023-05-16 2023-08-08 武汉大学 一种hyperIL-15与sCD4及Fc的融合蛋白及其应用
CN116554356B (zh) * 2023-05-16 2024-01-23 武汉大学 一种hyperIL-15与sCD4及Fc的融合蛋白及其应用
CN117645673A (zh) * 2023-11-22 2024-03-05 武汉大学 一种IL-21与sCD4及Fc的融合蛋白及其应用
CN117645673B (zh) * 2023-11-22 2024-05-10 武汉大学 一种IL-21与sCD4及Fc的融合蛋白及其应用

Also Published As

Publication number Publication date
WO2019129053A1 (zh) 2019-07-04
JP7336457B2 (ja) 2023-08-31
EP3733716A4 (en) 2021-11-24
CN111527109B (zh) 2024-11-01
JP2021511069A (ja) 2021-05-06
EP3733716A1 (en) 2020-11-04
US11970537B2 (en) 2024-04-30
US20200317787A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
CN111527109A (zh) 以抗体Fc区为骨架的融合蛋白二聚体及其应用
Kontermann Recombinant bispecific antibodies for cancer therapy
CN115057936B (zh) 异源二聚体多特异性抗体形式
Suryadevara et al. Are BiTEs the “missing link” in cancer therapy?
EP3638700B1 (en) Proteinaceous heterodimer and use thereof
GB2580228A (en) Immunostimulatory fusion molecules and uses thereof
AU2016288484B2 (en) Interleukin-15 fusion proteins for tumor targeting therapy
JP7356726B2 (ja) タンパク性ヘテロ二量体及びその使用
KR102629905B1 (ko) 항-pd-l1/항-pd-1 천연 항체 구조-유사 헤테로다이머 이중특이성 항체 및 그의 제조
CN108250303B (zh) 单域抗体融合蛋白及其应用
JP2018537415A (ja) 多価Ｆｖ抗体
US11352413B2 (en) Engineered PD-1 variants
EP4019536A1 (en) Immunocytokine, preparation for same, and uses thereof
Urbanska et al. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells
JP2014527515A (ja) 多価抗原結合Ｆｖ分子
JPWO2020247843A5 (zh)
CN115052897B (zh) PLAP-CD3ε双特异性抗体
US20220227827A1 (en) Proteinaceous heterodimer and use thereof
US20250333507A1 (en) Fusion protein of anti-tigit antibody and il2 or variant thereof, and application thereof
Wei et al. Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity
JP7398677B2 (ja) ウテログロビンを構造基盤とする二重特異性ポリペプチド
WO2021115333A1 (zh) 一种融合蛋白及表达此蛋白的工程化免疫细胞及其应用
CN102796199A (zh) 抗CD3抗体Fv片段与白介素3融合蛋白突变体、制备方法及其用途
Beha IL-15-based trifunctional antibody-fusion proteins with costimulatory TNF-superfamily ligands for cancer immunotherapy
Shuptrine et al. Bifunctional antibodies: preclinical and clinical applications

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment